arrow
K

Kaisa Sunela

University of Eastern Finland
H指数:13
被引数:452

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Low Risk of Central Nervous System Relapse Among Patients With T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Despite High-Risk Disease Presentation

尽管T细胞/组织细胞富集型大B细胞淋巴瘤具有高风险疾病表现,但患者中枢神经系统复发的风险较低

2026-08-010
OAAI
Socioeconomic Status and Access to Treatment in Diffuse Large B-Cell Lymphoma

社会经济地位与弥漫性大B细胞淋巴瘤的治疗可及性

2026-05-100
OAAI
Prolonged Time From Symptoms to Diagnosis Is Associated With an Inferior Progression-Free Survival in Diffuse Large B-Cell Lymphoma

症状到诊断的延长时间与弥漫性大B细胞淋巴瘤的不良无进展生存期相关

2025-11-230
OAAI
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)

与毒性相关的免疫治疗停药及结局:接受基于免疫联合治疗方案的晚期肾细胞癌患者(ARON-1研究)

2025-11-040
PRE
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study

基于免疫的组合疗法在非透明细胞肾细胞癌中/高风险患者中的应用:ARON-1研究的结果

2025-07-290
PRE
Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real-World Data

套细胞淋巴瘤的终生治疗轨迹: 基于模拟的20年真实世界数据分析

2025-01-080
PRE
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)
2024-09-070
OA
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

免疫肿瘤学联合治疗的晚期肾细胞癌和中度或低风险国际转移性肾细胞癌数据库联盟标准患者的真实世界结果: 风险组的差异有效性?

2024-02-0118
PRE
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
2023-08-018
OA